"At the current price, the stock is trading 16xFY09E and 12xFY10E, and the return ratios are at healthy levels of close to 37%. Though the stock has fallen by more than 10%, post the results, mainly on the back that the company has not revised its dollar revenue guidance and the fear that the BFSI vertical might experience much weaker revenue growth going forward. We believe it is an ideal opportunity to accumulate as the company would be growing its earnings close to 30%, and maintain our BUY rating with a price target of Rs 2250, which would give a return of 40% over the next one year," says Karvy's research report.
Tuesday, July 15, 2008
Stock Idea: Infosys Technologies
"At the current price, the stock is trading 16xFY09E and 12xFY10E, and the return ratios are at healthy levels of close to 37%. Though the stock has fallen by more than 10%, post the results, mainly on the back that the company has not revised its dollar revenue guidance and the fear that the BFSI vertical might experience much weaker revenue growth going forward. We believe it is an ideal opportunity to accumulate as the company would be growing its earnings close to 30%, and maintain our BUY rating with a price target of Rs 2250, which would give a return of 40% over the next one year," says Karvy's research report.
Disclaimer
The information in this publication is provided by http://www.moneybazzar.blogspot.com/ is intended for use for Readers & Traders . Every effort is made to provide accurate information, but http://www.moneybazzar.blogspot.com/ cannot guarantee the accuracy of the information or of the market analysis. This is a newsletter and is for informational purposes only. It is not a solicitation or offer to buy or sell futures. There is a high risk of loss in trading futures. You should not trade with money that you cannot afford to lose. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this newsletter. The past performance of any trading system or methodology is not necessarily indicative of future results.